TNXP vs. THTX, BLRX, RPHM, ANEB, MURA, CARM, RMTI, KZR, LEXX, and CASI
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Theratechnologies (THTX), BioLineRx (BLRX), Reneo Pharmaceuticals (RPHM), Anebulo Pharmaceuticals (ANEB), Mural Oncology (MURA), Carisma Therapeutics (CARM), Rockwell Medical (RMTI), Kezar Life Sciences (KZR), Lexaria Bioscience (LEXX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical preparations" industry.
Tonix Pharmaceuticals (NASDAQ:TNXP) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends.
Tonix Pharmaceuticals has a net margin of 0.00% compared to Theratechnologies' net margin of -23.04%. Theratechnologies' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.
Tonix Pharmaceuticals currently has a consensus target price of $176.00, indicating a potential upside of 7,863.80%. Given Tonix Pharmaceuticals' higher possible upside, equities research analysts clearly believe Tonix Pharmaceuticals is more favorable than Theratechnologies.
Tonix Pharmaceuticals has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
Tonix Pharmaceuticals received 310 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 63.48% of users gave Tonix Pharmaceuticals an outperform vote while only 52.73% of users gave Theratechnologies an outperform vote.
In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Theratechnologies. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 0 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 1.00 beat Tonix Pharmaceuticals' score of -0.75 indicating that Theratechnologies is being referred to more favorably in the news media.
82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 0.5% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Theratechnologies has higher revenue and earnings than Tonix Pharmaceuticals. Theratechnologies is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Tonix Pharmaceuticals beats Theratechnologies on 11 of the 17 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
